Get started

Biotech

ONTX - Could Breakout, How Far?All, ONTX is overdue for a takeoff. Today it is at +30% premarket, but this is why you do TA and watch Volume at open. It will gap above both blue lines for support and .44/.45 are aboth huge support lines. My theory is simple it may sell off around .53. However, I would hold and wait for the rally at .39 or .44 to push back up to .70-.75. The question there becomes will it break or fail that area on second re test? ALSO FIRST THING IS FIRST WATCH THE MARKET BEFORE YOU BUY ANY STOCK. S&P / NASDAQ AND WATCH VOLUME ON INVERSE S&P ETFS.
OLong
by DigitalData
ABBV an Entry Point into the Wild World of BiotechBiotechnology and pharmaceutical companies have been quickly cycling through overbought and oversold. The problem has been so problematic that Sorrento Therapeutics had to specifically claim they were not a “pump and dump” scheme. Any whisper of a "cure" for Covid-19 has investors rushing to the entrance and quickly fleeing after results are what they had expected (an image of people rushing toward the exit and getting stuck in door comes to my mind). People who know the biotech sector have been cautiously watching the spectacle and trying to avoid getting trampled in a stampede. To be clear: your average investor is getting burned in the vaccine-hunt game. AbbVie "ABBV" is (and has been) a reliable pharmaceutical and biotechnology company for some time. The company is known for its generous dividend – previously at a yield of 5.20%. The company has a robust balance sheet with a Quick Ratio of 3.03 and a Current Ratio of 3.14. In the world of biotech, research and development is everything. ABBV pipeline is stacked with potential drug candidates many of which are in Phase 3 of development according to AbbVie’s investor relations brochure. From a technical analysis standpoint, the moving averages appear to be moving toward a positive crossover – EMA10 = 91.00, EMA20 = 90.88 EMA25 = 90.87. The stock does not look overbought or oversold according to the Stoch RSI and Money Flow Indicator. However, the MACD indicator shows that there may be a further swing downward before moving into positive territory. Finally, the linear regression model is one of the few biotechnology companies that is not inverse or appears caught in a sideway pattern. LONG ABBV purchased today (06-02-2020) @ 90.86.
NYSE:ABBVLong
by luminaryfi
6
QLGN - RTTR Merger - Soon to Bounce +30-85% Once it DoesAll, I think we are coming to a double bottom soon. The weekly on QLGN it's obvious there was a massive double top + merger made it sail down. The Question here is where does it end? It is essentially down over 45%. It is going to hit that trend line coming down and most likely fail if you want to swing that. Overall it will recover just a matter of how long. ** DISCLAIMER: If one of there pipeline news comes out thats positive this went down so fast that it will skyrocket on news. So pay attention** Levels I would look at at buy ins Possible bounce now. $5.80 $5.30 Alerts at buy in levels ALSO alerts above current level like 5-10% starting now. that way you get alerted if it does start to take off. Remeber to use volume and make sure it's actually breaking out or has news. Not just some pump on a lower timeframe. Wait for a daily candle. QLGN - RTTR Merger - Soon to Bounce
NASDAQ:QLGN
by DigitalData
$MRNA$MRNA Bullish falling wedge Resistance: 65.16 Support: 47.56 Buy: $56.40 Stop loss: $50.99 Limit sell: $63.90 Notes: Still feel sketch about their "Secondary offering" it tells shareholders that they are going to take a giant ass pile of cash and set it on fire. However, as will all offerings... someone has to make money so you can decide if it is worth a longer term hold. Does the 3x run up justify its price. They just got caught saying they had "positive results" on a 45 person study and then redacted those comments.
NASDAQ:MRNA
by IMF_Trading
$WVE can rise in the next daysContextual immersion trading strategy idea. Wave Life Sciences is a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereo pure oligonucleotides through PRISM, a discovery and drug developing platform. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $11,16; stop-loss — $10,03. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:WVELong
by KozakHlib
2
Vaccine Stock Mania pushes Moderna to a $29bn Market Cap- On Monday there was news that Moderna’s Covid-19 vaccine candidate is generating an immune response in Phase 1 trial subjects. - We also then saw massive buying push the market cap to now $29 billion. This is NOT a proven company and doesn't have any marketable product YET. - Some concern has since been expressed by Vaccine experts others on on when company will release full data / research here and that a vaccine is still a long way away. - Anyway you know the drill here - if you think this is THE Vaccine company then try and find a way into this stock - don't mortgage your house / have a plan and put a small % to work. - Technically massive uptrend and probably a 2 places to get long - either at the immediate demand zone ($66ish) or the $50ish. There is some negative divergence kicking in with the Connor's RSI and so a bigger dip here is possible.
NASDAQ:MRNALong
by Tuhi_Capital
$MDGL can rise in the next daysContextual immersion trading strategy idea. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $118,32; stop-loss — $114,98. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:MDGLLong
by KozakHlib
2